Boundless Bio Presents Preclinical Data on the Discovery of its Second ecDNA-Directed Therapeutic Candidate, BBI-825, at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Preclinical findings support the advancement of BBI-825, a novel, orally available, selective inhibitor of ribonucleotide reductase (RNR), as a differentiated treatment approach for ecDNA-enabled oncogene or resistance gene amplified cancers, including resistance associated with treatment of KRAS^G12C mutant colorectal cancer (CRC)

A second poster presentation reveals insight into the intrinsic genomic plasticity of extrachromosomal DNA (ecDNA) across dynamic states of extrachromosomal and chromosomal-based amplification in cancer cells

Excerpt from the Press Release:

SAN DIEGO–(BUSINESS WIRE)–Boundless Bio, a clinical stage, next-generation precision oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today will present preclinical data on its second ecDNA-directed therapy (ecDTx), BBI-825, as well as present additional research on the intrinsic genomic plasticity of cancer cells enabled by ecDNA at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

BBI-825 is a novel, orally available, selective inhibitor of ribonucleotide reductase (RNR), which is a rate-limiting enzyme in the cellular production of deoxynucleotide triphosphates (dNTPs), essential building blocks for ecDNA assembly and repair in cancer cells. BBI-825 has demonstrated RNR inhibition in a host of tumor cell lines and tumor regressions in ecDNA-enabled preclinical cancer models and is currently being evaluated in Investigational New Drug (IND)-enabling studies. BBI-825 was discovered using Boundless Bio’s proprietary Spyglass platform, a drug discovery engine to identify and preclinically validate targets that are essential for cancer cells’ reliance on ecDNA for growth, treatment resistance, and survival.

“We are excited to unveil our second ecDTx program, BBI-825, which has demonstrated promising preclinical proof of concept in multiple tumor types and across different oncogene amplifications, particularly in resistance associated with targeted therapy treatment of MAPK pathway activated cancers,” said Chris Hassig, Ph.D., Chief Scientific Officer of Boundless Bio

Click the button below to read the entire Press Release:

Continue Reading The Press Release